DR info

臨床試験数 : 42 / 薬物数 : 24 - (DrugBank : 4) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 48

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

ACZ885
   NOVARTIS FARMA
      2008   -   EUCTR2007-004367-22-IT   France;Germany;Italy;Spain;United Kingdom;
   Novartis Farmacéutica S.A
      2012   -   EUCTR2011-005154-57-ES   Belgium;Canada;France;Germany;Israel;Spain;United Kingdom;
   Novartis Pharma Services AG
      2013   Phase 3   EUCTR2011-005154-57-GB   Belgium;Canada;France;Germany;Israel;Spain;United Kingdom;
      2013   Phase 3   EUCTR2009-016859-22-FR   Belgium;France;Germany;Ireland;Spain;United Kingdom;
      2013   -   EUCTR2011-005154-57-FR   Belgium;Canada;France;Germany;Israel;Spain;United Kingdom;
      2012   Phase 3   EUCTR2011-005154-57-BE   Belgium;Canada;France;Germany;Israel;Spain;United Kingdom;
      2012   -   EUCTR2011-005154-57-DE   Belgium;Canada;France;Germany;Israel;Spain;United Kingdom;
      2010   Phase 3   EUCTR2009-016859-22-GB   Belgium;France;Germany;Ireland;Spain;United Kingdom;
      2010   -   EUCTR2009-016859-22-BE   Belgium;France;Germany;Spain;United Kingdom;
      2009   -   EUCTR2007-004367-22-BE   Belgium;France;Germany;Italy;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-004367-22-GB   Belgium;France;Germany;Italy;Spain;United Kingdom;
      2008   -   EUCTR2007-004367-22-FR   Belgium;France;Germany;Italy;Spain;United Kingdom;
      2008   -   EUCTR2007-004367-22-DE   France;Germany;Italy;Spain;United Kingdom;
      -   Phase 3   EUCTR2009-016859-22-IE   Belgium;Canada;France;Germany;Ireland;Israel;Spain;Switzerland;United Kingdom;
      -   -   EUCTR2009-016859-22-Outside-EU/EEA   Canada;Israel;Switzerland;
      -   -   EUCTR2008-001429-32-Outside-EU/EEA   United States;
      -   -   EUCTR2007-004367-22-Outside-EU/EEA   India;Turkey;United States;
   Novartis Pharmaceuticals
      2012   Phase 3   NCT01576367   Belgium;Canada;France;Germany;Spain;Switzerland;United Kingdom;
      2010   Phase 3   NCT01302860   Belgium;Canada;France;Germany;Spain;Switzerland;United Kingdom;
      -   -   EUCTR2015-003491-69-Outside-EU/EEA   Canada;
      -   -   EUCTR2015-003490-15-Outside-EU/EEA   Japan;
ACZ885 drug substance
   Novartis Pharma Services AG
      2007   -   EUCTR2004-002980-26-FR   France;Germany;Spain;United Kingdom;
ATI-450
   Aclaris Therapeutics, Inc.
      2020   Phase 2   NCT04524858   United States;
Anakinra
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2003   Phase 1/Phase 2   NCT00069329   United States;
Anti-interleukin-1B monoclonal antibody
   NOVARTIS FARMA
      2008   -   EUCTR2007-004367-22-IT   France;Germany;Italy;Spain;United Kingdom;
C-028380
   Inflazome (Australia) Pty Ltd.
      2020   Phase 2   EUCTR2020-000489-40-GB   Australia;Ireland;United Kingdom;
Canakinumab
   Novartis Pharmaceuticals
      2009   Phase 3   NCT00991146   Japan;
      2009   Phase 3   NCT00770601   United States;
Canakinumab (ACZ885)
   Novartis
      2008   Phase 3   NCT00685373   Belgium;France;Germany;India;Italy;Spain;Turkey;United Kingdom;United States;
Canakinumab (WHO approval pending)
   Novartis Pharma Services AG
      2009   -   EUCTR2007-004367-22-BE   Belgium;France;Germany;Italy;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-004367-22-GB   Belgium;France;Germany;Italy;Spain;United Kingdom;
      2008   -   EUCTR2007-004367-22-FR   Belgium;France;Germany;Italy;Spain;United Kingdom;
      2008   -   EUCTR2007-004367-22-DE   France;Germany;Italy;Spain;United Kingdom;
Canakinumab (company code: ACZ885D)
   Novartis Pharmaceuticals
      2010   Phase 3   NCT01105507   Canada;
DFV890
   NOVARTIS PHARMA AG
      2021   Phase 1;Phase 2   EUCTR2020-005948-33-IT   Germany;Italy;United States;
   Novartis Pharma AG
      2021   Phase 2   EUCTR2020-005948-33-DE   Germany;Italy;United States;
   Novartis Pharmaceuticals
      2021   Phase 2   NCT04868968   Germany;Italy;United States;
IZD174
   Inflazome (Australia) Pty Ltd.
      2020   Phase 2   EUCTR2020-000489-40-GB   Australia;Ireland;United Kingdom;
IZD334
   Inflazome UK Ltd
      2019   Phase 1   NCT04086602   Australia;
Ilaris
   Novartis Pharmaceuticals
      -   -   EUCTR2015-003491-69-Outside-EU/EEA   Canada;
      -   -   EUCTR2015-003490-15-Outside-EU/EEA   Japan;
   UZ Leuven
      2014   -   EUCTR2014-001393-34-BE   Belgium;
Inzomelid
   Inflazome (Australia) Pty Ltd.
      2020   Phase 2   EUCTR2020-000489-40-GB   Australia;Ireland;United Kingdom;
Kineret
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      -   -   EUCTR2013-000300-42-Outside-EU/EEA   United States;
Recombinant human monoclonal antibody to human IL-1Beta of the IgG1/K class
   Novartis Pharma Services AG
      2013   Phase 3   EUCTR2009-016859-22-FR   Belgium;France;Germany;Ireland;Spain;United Kingdom;
      2010   Phase 3   EUCTR2009-016859-22-GB   Belgium;France;Germany;Ireland;Spain;United Kingdom;
      2010   -   EUCTR2009-016859-22-DE   Belgium;France;Germany;Spain;United Kingdom;
      2010   -   EUCTR2009-016859-22-BE   Belgium;France;Germany;Spain;United Kingdom;
Recombinant human monoclonal antibody to human IL-1beta of the IgG1/K class
   Novartis Pharma Services AG
      2009   -   EUCTR2007-004367-22-BE   Belgium;France;Germany;Italy;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-004367-22-GB   Belgium;France;Germany;Italy;Spain;United Kingdom;
      2008   -   EUCTR2007-004367-22-FR   Belgium;France;Germany;Italy;Spain;United Kingdom;
      2008   -   EUCTR2007-004367-22-DE   France;Germany;Italy;Spain;United Kingdom;
Rilonacept
   Charite University, Berlin, Germany
      2009   Phase 2   NCT01045772   Germany;
   Charité Universitätsmedizin Berlin, Department of Dermatology and Allergy
      2008   -   EUCTR2006-004290-97-DE   Germany;
   Regeneron Pharmaceuticals
      2005   Phase 3   NCT00288704   United States;
Tranilast
   Peking Union Medical College Hospital
      2019   Phase 2   NCT03923140   China;
XOMA 052
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2010   Phase 1/Phase 2   NCT01211977   United States;